C

CSPC Pharmaceutical Group Ltd
HKEX:1093

Watchlist Manager
CSPC Pharmaceutical Group Ltd
HKEX:1093
Watchlist
Price: 8.83 HKD -0.67% Market Closed
Market Cap: 101.7B HKD

CSPC Pharmaceutical Group Ltd
Total Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

CSPC Pharmaceutical Group Ltd
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Total Assets
ÂĄ46B
CAGR 3-Years
6%
CAGR 5-Years
10%
CAGR 10-Years
15%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Assets
ÂĄ35.1B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Assets
ÂĄ17.5B
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
16%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Assets
ÂĄ68.3B
CAGR 3-Years
19%
CAGR 5-Years
16%
CAGR 10-Years
20%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Assets
ÂĄ54.5B
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
11%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Assets
ÂĄ7.1B
CAGR 3-Years
96%
CAGR 5-Years
46%
CAGR 10-Years
N/A
No Stocks Found

CSPC Pharmaceutical Group Ltd
Glance View

Market Cap
101.7B HKD
Industry
Pharmaceuticals

CSPC Pharmaceutical Group Ltd., a prominent player in the pharmaceutical industry, has charted a strategic path focused on innovation and a diversified portfolio. The company, with its roots in China, has emerged as a formidable force by blending traditional pharmaceutical manufacturing with a strong emphasis on research and development. CSPC's journey is characterized by a commitment to developing high-quality generic drugs, innovative therapeutics, and nutritional products. The company's core business revolves around the production and sale of a wide range of pharmaceuticals, including cardiovascular drugs, oncology treatments, and central nervous system therapies. By leveraging advanced technology and robust research initiatives, CSPC consistently delivers solutions that address both common and complex healthcare needs across the globe. With a strategic focus on both domestic and international markets, CSPC Pharmaceutical Group capitalizes on its extensive distribution network to maximize reach and impact. The company has made significant investments in its production capabilities to maintain stringent quality standards while achieving cost efficiency. Furthermore, CSPC's earnings are bolstered by its expanding pipeline of innovative drugs, developed in-house and through strategic collaborations, which aims to capture emerging therapeutic areas. Overall, CSPC's blend of traditional pharmaceutical expertise, a focus on innovation, and strategic market positioning enables it to maintain a strong operational foothold and to consistently drive revenue growth in an ever-evolving industry landscape.

Intrinsic Value
7.86 HKD
Overvaluation 11%
Intrinsic Value
Price
C

See Also

What is CSPC Pharmaceutical Group Ltd's Total Assets?
Total Assets
46B CNY

Based on the financial report for Sep 30, 2025, CSPC Pharmaceutical Group Ltd's Total Assets amounts to 46B CNY.

What is CSPC Pharmaceutical Group Ltd's Total Assets growth rate?
Total Assets CAGR 10Y
15%

Over the last year, the Total Assets growth was -4%. The average annual Total Assets growth rates for CSPC Pharmaceutical Group Ltd have been 6% over the past three years , 10% over the past five years , and 15% over the past ten years .

Back to Top